Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.

Introduction: Ruxolitinib is widely used in myelofibrosis (MF). However, some patients do not optimally respond and require more efficacious treatment. Our analysis aimed to establish predictors of ruxolitinib response.

Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).

We present the results of a prospective, non-randomized phase 2 trial in which 253 AML patients (pts) under 60 years old received DAC (Daunorubicin + AraC + Cladribine) as first induction followed by CLAM (Cladribine + AraC + Mitoxantrone) as early second induction on day 16 based on bone marrow (BM) blasts on day 14 (D14). The CR/CRi rate after a single course of DAC was 83% for pts with D14 BM blasts less than 10%. Forty-six pts had >10% BM blasts on D14, of whom 35 received CLAM with rates of CR/CRi 60% and early death (ED) 23%.

[Influence of salmon calcitonin on changes in thyroid hormone concentration and on TSH secretion. II].

The aim of this investigation was determination of salmon calcitonin (SC) administration influence on hypothalamus-pituitary-thyroid axis. The investigation was carried out on a group of 26 patients. The group was divided in two different ways: into people younger and older than 65 years, and into men and women.

[The influence of salmon calcitonin on changes in thyroid hormone concentration and on TSH secretion. I].

The aim of this investigation was determination of salmon calcitonin (sCT) influence on changes of thyroid hormones levels in serum. The investigation was carried out on a group of 26 patients. The group was divided in two different ways: into people younger and older than 65 years, and into men and women.